Prelude Therapeutics is a biotechnology business based in the US. Prelude Therapeutics shares (PRLD) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.89 – an increase of 0.09% over the previous week. Prelude Therapeutics employs 131 staff and has a trailing 12-month revenue of around $7 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.89 |
|---|---|
| 52-week range | $0.61 - $6.80 |
| 50-day moving average | $0.76 |
| 200-day moving average | $2.05 |
| Wall St. target price | $3.33 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.68 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.8874 from 2025-05-02
| 1 week (2025-04-28) | 0.09% |
|---|---|
| 1 month (2025-04-04) | 31.47% |
| 3 months (2025-02-05) | -24.15% |
| 6 months (2024-11-05) | -31.21% |
| 1 year (2024-05-03) | -77.01% |
|---|---|
| 2 years (2023-05-04) | -85.45% |
| 3 years (2022-05-04) | 4.61 |
| 5 years (2020-05-01) | N/A |
| Revenue TTM | $7 million |
|---|---|
| Gross profit TTM | $7 million |
| Return on assets TTM | -38.54% |
| Return on equity TTM | -69.01% |
| Profit margin | 0% |
| Book value | $2.38 |
| Market Capitalization | $50.1 million |
TTM: trailing 12 months
We're not expecting Prelude Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Prelude Therapeutics's shares have ranged in value from as little as $0.6101 up to $6.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Prelude Therapeutics's is 1.339. This would suggest that Prelude Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Prelude Therapeutics's beta into context you can compare it against those of similar companies.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. .
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.